Davenport & Co’s Elevance Health ELV Stock Holding History

Davenport & Co’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$171M	Sell	441,940 -132,072	-23%	-$49M	0.84%	24
2026 Q1	$167M	Sell	574,012 -1,771	-0.3%	-$582K	0.91%	20
2025 Q4	$202M	Sell	575,783 -54,420	-9%	-$18.4M	1.07%	16
2025 Q3	$203M	Buy	630,203 +353,748	+128%	+$110M	1.08%	15
2025 Q2	$107M	Sell	276,455 -5,419	-2%	-$2.18M	0.58%	53
2025 Q1	$122M	Buy	281,874 +53,811	+24%	+$21.6M	0.71%	40
2024 Q4	$84.1M	Buy	228,063 +44,502	+24%	+$18.6M	0.48%	75
2024 Q3	$95.6M	Sell	183,561 -59,837	-25%	-$32M	0.54%	67
2024 Q2	$132M	Sell	243,398 -1,177	-0.5%	-$622K	0.79%	29
2024 Q1	$127M	Sell	244,575 -4,382	-2%	-$2.18M	0.78%	33
2023 Q4	$117M	Sell	248,957 -1,116	-0.4%	-$516K	0.8%	32
2023 Q3	$110M	Buy	250,073 +2,132	+0.9%	+$967K	0.83%	34
2023 Q2	$110M	Buy	247,941 +1,273	+0.5%	+$587K	0.81%	35
2023 Q1	$113M	Buy	246,668 +63,253	+34%	+$30.1M	0.89%	25
2022 Q4	$94.1M	Buy	183,415 +75	+0%	+$38.1K	0.77%	40
2022 Q3	$83.4M	Buy	183,340 +1,671	+0.9%	+$800K	0.72%	42
2022 Q2	$87.7M	Sell	181,669 -301	-0.2%	-$149K	0.72%	43
2022 Q1	$89.8M	Buy	181,970 +1,729	+1%	+$790K	0.61%	57
2021 Q4	$83.5M	Buy	180,241 +5,405	+3%	+$2.27M	0.55%	65
2021 Q3	$65.2M	Buy	174,836 +157,007	+881%	+$59.7M	0.46%	79
2021 Q2	$6.81M	Sell	17,829 -53	-0.3%	-$20.3K	0.05%	189
2021 Q1	$6.42M	Sell	17,882 -639	-3%	-$205K	0.06%	170
2020 Q4	$5.95M	Buy	18,521 +87	+0.5%	+$26.7K	0.06%	167
2020 Q3	$4.95M	Buy	18,434 +65	+0.4%	+$17.5K	0.06%	161
2020 Q2	$4.83M	Sell	18,369 -58	-0.3%	-$15.5K	0.06%	156
2020 Q1	$4.18M	Sell	18,427 -2,845	-13%	-$775K	0.06%	155
2019 Q4	$6.42M	Buy	21,272 +1,898	+10%	+$522K	0.07%	150
2019 Q3	$5.47M	Sell	19,374 -306	-2%	-$83.8K	0.07%	157
2019 Q2	$5.55M	Buy	19,680 +924	+5%	+$252K	0.07%	154
2019 Q1	$5.38M	Buy	18,756 +830	+5%	+$240K	0.07%	153
2018 Q4	$4.71M	Buy	17,926 +546	+3%	+$150K	0.06%	157
2018 Q3	$4.76M	Buy	17,380 +2,832	+19%	+$735K	0.06%	171
2018 Q2	$3.46M	Sell	14,548 -396	-3%	-$91.7K	0.04%	187
2018 Q1	$3.28M	Buy	14,944 +293	+2%	+$68.8K	0.04%	188
2017 Q4	$3.3M	Buy	14,651 +555	+4%	+$118K	0.04%	184
2017 Q3	$2.68M	Sell	14,096 -850	-6%	-$162K	0.03%	191
2017 Q2	$2.81M	Sell	14,946 -922	-6%	-$166K	0.04%	182
2017 Q1	$2.28M	Sell	15,868 -55	-0.3%	-$8.75K	0.03%	199
2016 Q4	$2.29M	Sell	15,923 -1,626	-9%	-$218K	0.03%	193
2016 Q3	$2.2M	Sell	17,549 -312	-2%	-$40.3K	0.03%	196
2016 Q2	$2.35M	Sell	17,861 -187,461	-91%	-$25.6M	0.04%	192
2016 Q1	$28.5M	Sell	205,322 -1,358	-0.7%	-$181K	0.45%	89
2015 Q4	$28.8M	Buy	206,680 +672	+0.3%	+$92.6K	0.47%	80
2015 Q3	$28.8M	Sell	206,008 -3,757	-2%	-$565K	0.48%	80
2015 Q2	$34.4M	Sell	209,765 -330,016	-61%	-$52.7M	0.53%	75
2015 Q1	$83.3M	Sell	539,781 -1,912	-0.4%	-$272K	1.28%	13
2014 Q4	$68.1M	Sell	541,693 -2,605	-0.5%	-$322K	1.1%	19
2014 Q3	$65.1M	Sell	544,298 -217,761	-29%	-$25M	1.14%	20
2014 Q2	$82M	Buy	762,059 +3,374	+0.4%	+$348K	1.39%	12
2014 Q1	$75.5M	Buy	758,685 +5,714	+0.8%	+$517K	1.37%	13
2013 Q4	$69.6M	Buy	752,971 +7,980	+1%	+$709K	1.3%	17
2013 Q3	$62.3M	Sell	744,991 -49,208	-6%	-$4.22M	1.28%	20
2013 Q2	$65M	Buy	+794,199	New	+$59.4M	1.43%	16

Other funds holding ELV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Canoe Financial Calgary, Alberta, Canada $8.07B AUM 25.47% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MIHAS

Maj Invest Holding A/S Copenhagen K, Denmark $2.2B AUM 25.64% 1-Year Est. Return

ZIC

ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PAS

Professional Advisory Services Vero Beach, Florida $836M AUM 25.79% 1-Year Est. Return

Rockland Trust Hanover, Massachusetts $2.55B AUM 17.04% 1-Year Est. Return

Davenport & Co's ELV Position: Q2 2026 in Review

Davenport & Co reduced its Elevance Health (ELV) stake by 23% in Q2 2026, selling an estimated $49M and leaving 441,940 shares worth $171M. The position accounts for 0.84% of the portfolio, ranked #24.

Davenport & Co first reported a position in ELV in Q2 2013 and has held it in 53 quarters since. The position peaked at $203M in Q3 2025. 222 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

Davenport & Co held 441,940 shares of Elevance Health worth $171M as of Q2 2026.
Davenport & Co sold 132,072 Elevance Health shares in Q2 2026, an estimated $49M.
Elevance Health made up 0.84% of Davenport & Co's portfolio in Q2 2026, its #24 holding.
Davenport & Co first reported a position in Elevance Health in Q2 2013 and has held it in 53 quarters since.
Davenport & Co's Elevance Health position peaked at $203M in Q3 2025.
222 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.